We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease
Read MoreHide Full Article
Galapagos NV (GLPG - Free Report) announced that it has dosed the first patient in a phase III study – DIVERSITY – on filgotinib for the treatment of Crohn’s disease. This triggered a milestone payment worth $50 million from Gilead Sciences Inc. (GILD - Free Report) .
The study will evaluate the safety and efficacy of once-daily filgotinib (100 mg and 200 mg), compared to placebo, in patients with moderately-to-severely active Crohn’s disease, including those who failed previous biological therapy.
We remind investors that in Dec 2015, Galapagos signed a collaboration agreement with Gilead for the development and commercialization of filgotinib for inflammatory indications including rheumatoid arthritis (RA), Crohn’s disease and ulcerative colitis.
In Aug 2016, Gilead initiated a phase III program (FINCH) on filgotinib in RA. The FINCH program comprises three studies that will evaluate the safety and efficacy of once-daily filgotinib (100 mg and 200 mg) in patients from early stage to biologic-experienced.
Moreover, Gilead expects to start a phase II/III study for the treatment of ulcerative colitis later in the quarter.
Meanwhile, Galapagos continues to progress on its cystic fibrosis programs, with partner AbbVie Inc. (ABBV - Free Report) conducting several phase I and II studies.
Going forward, we expect investor focus to remain on further pipeline updates from the company.
Vanda’s loss estimates narrowed from 68 cents per share to 56 cents for 2016 over the last 60 days, while its earnings estimates increased from 16 cents per share to 17 cents for 2017. The company posted a positive earnings surprise in three of the last four quarters with an average beat of 56.65%. Its share price has surged 80% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease
Galapagos NV (GLPG - Free Report) announced that it has dosed the first patient in a phase III study – DIVERSITY – on filgotinib for the treatment of Crohn’s disease. This triggered a milestone payment worth $50 million from Gilead Sciences Inc. (GILD - Free Report) .
The study will evaluate the safety and efficacy of once-daily filgotinib (100 mg and 200 mg), compared to placebo, in patients with moderately-to-severely active Crohn’s disease, including those who failed previous biological therapy.
We remind investors that in Dec 2015, Galapagos signed a collaboration agreement with Gilead for the development and commercialization of filgotinib for inflammatory indications including rheumatoid arthritis (RA), Crohn’s disease and ulcerative colitis.
In Aug 2016, Gilead initiated a phase III program (FINCH) on filgotinib in RA. The FINCH program comprises three studies that will evaluate the safety and efficacy of once-daily filgotinib (100 mg and 200 mg) in patients from early stage to biologic-experienced.
Moreover, Gilead expects to start a phase II/III study for the treatment of ulcerative colitis later in the quarter.
Meanwhile, Galapagos continues to progress on its cystic fibrosis programs, with partner AbbVie Inc. (ABBV - Free Report) conducting several phase I and II studies.
Going forward, we expect investor focus to remain on further pipeline updates from the company.
GALAPAGOS -ADR Price
GALAPAGOS -ADR Price | GALAPAGOS -ADR Quote
Currently, Galapagos carries a Zacks Rank #3 (Hold).
Stock to Consider
Vanda Pharmaceuticals, Inc. (VNDA - Free Report) is a better-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Vanda’s loss estimates narrowed from 68 cents per share to 56 cents for 2016 over the last 60 days, while its earnings estimates increased from 16 cents per share to 17 cents for 2017. The company posted a positive earnings surprise in three of the last four quarters with an average beat of 56.65%. Its share price has surged 80% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>